KDR and cancer: However, several recent studies have revealed that antiangiogenic therapy is not always beneficial for treating cancer because excessive blockade of VEGFR2 signaling activates the infiltration of immunosuppressive innate immune cells, such as Ly6Clow monocytes, which in turn promote tumor growth40–42.